NIVEN RALPH 4

Accession 0001415889-24-000818

CIK 0001798749other

View on SEC.gov Company Profile

Filed

Jan 7, 7:00 PM ET

Accepted

Jan 8, 6:00 PM ET

Size

22.1 KB

Accession

0001415889-24-000818

Insider Transaction Report

Form 4

Period: 2024-01-05

Aerovate Therapeutics, Inc.AVTE

NIVEN RALPH

Chief Development Officer

Transactions

Exercise/Conversion
Common Stock
2024-01-05$2.14/sh+3,200$6,848→ 6,209 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-05−900→ 14,208 total
Exercise: $1.74Exp: 2030-09-03→ Common Stock (900 underlying)
Sale
Common Stock
2024-01-05$18.67/sh−2,126$39,695→ 4,083 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-05−500→ 11,394 total
Exercise: $2.14Exp: 2031-04-01→ Common Stock (500 underlying)
Exercise/Conversion
Common Stock
2024-01-05$1.74/sh+1,400$2,436→ 3,009 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-05−1,200→ 36,108 total
Exercise: $2.14Exp: 2031-04-01→ Common Stock (1,200 underlying)
Sale
Common Stock
2024-01-05$19.57/sh−2,474$48,421→ 1,609 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-05−500→ 9,588 total
Exercise: $1.74Exp: 2030-09-03→ Common Stock (500 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-01-05−1,500→ 43,232 total
Exercise: $2.14Exp: 2031-04-01→ Common Stock (1,500 underlying)

Footnotes (8)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.315 to $19.30, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
[F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.375 to $19.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request
[F4]A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
[F5]A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
[F6]A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
[F7]A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
[F8]A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

Documents

1 file

4
form4-01082024_060101.xmlPrimary

Issuer

Aerovate Therapeutics, Inc.

CIK 0001798749

→

Entity typeother

Related Parties

filerCIK 0001168060

Filing Metadata

Form type: 4
Filed: Jan 7, 7:00 PM ET
Accepted: Jan 8, 6:00 PM ET
Size: 22.1 KB

View on SEC.gov